GHRP-2 Side Effects

Known side effects

The following side effects have been reported in research studies and user reports for GHRP-2:

• Cortisol elevation: GHRP-2 raises cortisol transiently after each injection, with peak increases occurring at approximately 30 minutes and returning to baseline within 2 to 3 hours. Frequent dosing (more than 3 times daily) may sustain cortisol elevation and impair recovery or sleep quality (PMID: 15265848)
• Prolactin elevation: Measurable prolactin increases follow each injection through GHS-R1a activation in pituitary lactotrophs. Sustained prolactin elevation with high-dose or high-frequency protocols may cause gynecomastia risk in men or menstrual irregularities in women
• Appetite stimulation: Noticeable hunger typically begins within 20 to 30 minutes of injection and lasts 1 to 2 hours. Less severe than GHRP-6 but more pronounced than ipamorelin. Timing injections before planned meals can convert this side effect into a practical benefit
• Water retention: GH elevation drives fluid retention through aldosterone and antidiuretic hormone interactions. Transient bloating and mild edema are common in the first few weeks of use and typically resolve as the body adapts to elevated GH signaling
• Injection site reactions: Localized redness, mild swelling, or itching at the injection site occur with subcutaneous administration, particularly when injecting the same site repeatedly. Rotating injection sites minimizes this effect
• Tingling or numbness: Some research subjects report transient peripheral tingling, particularly in the hands, consistent with GH-mediated fluid shifts and effects on peripheral nerves. This effect is typically mild and resolves within hours
• Potential for receptor desensitization with very high-dose or very high-frequency protocols, though GHRP-2 desensitizes more slowly than hexarelin. Standard 2 to 3 times daily protocols at 100 to 200 mcg appear to preserve receptor sensitivity across typical cycle lengths

Severity and frequency

Limited clinical data is available for GHRP-2. Side effect frequency and severity are based on available research and anecdotal reports. More data is needed for definitive safety profiles.

When to seek medical attention

Contact your healthcare provider immediately if you experience:

• Severe or persistent symptoms that do not improve
• Signs of an allergic reaction (rash, swelling, difficulty breathing)
• Severe abdominal pain
• Changes in vision or neurological symptoms
• Any symptom that concerns you

Risk factors

Side effect risk may be higher in certain populations. Discuss your complete medical history with your doctor, including:

• Pre-existing medical conditions
• Current medications (drug interactions)
• Pregnancy or plans to become pregnant
• History of allergic reactions to peptides or similar compounds
• Note: GHRP-2 is a research compound without established human safety data from FDA-approved clinical trials

Research references

• Comparison of growth hormone (GH)-releasing peptides: stimulation of GH release from perifused rat anterior pituitaries by GHRP-1, GHRP-2, GHRP-6, hexarelin, and MK-0677 — Endocrinology (1997) [PubMed]
• Growth hormone (GH)-releasing peptide-2 administration elevates GH and insulin-like growth factor-I concentrations and enhances nitrogen retention in normal subjects — Journal of Clinical Endocrinology and Metabolism (2004) [PubMed]
• Mechanism of action of growth hormone-releasing peptides — Endocrine Reviews (1999) [PubMed]